Core Insights - Aytu BioPharma reported net revenue of $15.2 million for Q2 2026, with ADHD portfolio revenue at $13.2 million, reflecting a slight decrease due to a strategic shift towards launching EXUA, the first FDA-approved 5HT1A agonist for treating major depressive disorder (MDD) [12][18] - The commercial launch of EXUA is supported by a targeted marketing strategy, including a strong sales team and the RX Connect platform to ensure patient access and minimize costs [13][19] - Management emphasized a cautious approach towards expanding the salesforce, contingent on achieving profitability and cash flow from EXUA sales [13][22] Financial Performance - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million [18] - Gross margin decreased to 63.5% due to transition-related expenses, but would have been 67.4% excluding a $600,000 inventory write-down [13][18] - The company reported a net loss of $10.6 million or $1.05 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [18] Product Launch and Strategy - EXUA was launched with early prescriptions written in 27 states, and over 100 doctors have prescribed it within the first month [12][19] - The RX Connect platform is designed to minimize administrative burdens for patients and prescribers, ensuring predictable coverage for commercially insured patients [13][19] - The marketing strategy includes a mix of personal and non-personal approaches, focusing on high-volume antidepressant prescribers and leveraging insights from the RX Connect platform [19][23] Market Context - Major depressive disorder affects an estimated 21 million US adults, with a significant portion of patients failing to achieve remission with traditional SSRIs and SNRIs [16][19] - The ADHD portfolio continues to perform above expectations despite a slight revenue decrease, attributed to a strategic shift towards EXUA [18][19] - The company has $30 million in cash and cash equivalents, with ongoing investments focused on EXUA's launch [14][18]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

分组1 - Aytu BioPharma Inc. reported a quarterly loss of $1.05 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.26, marking an earnings surprise of -303.85% [1] - The company posted revenues of $15.17 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 26.27%, although this represents a decline from year-ago revenues of $16.22 million [2] - Aytu BioPharma shares have increased by approximately 4.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $12.7 million, and for the current fiscal year, it is -$0.54 on revenues of $52.63 million [7] - The Medical - Biomedical and Genetics industry, to which Aytu BioPharma belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Illumina, is expected to report quarterly earnings of $1.26 per share, reflecting a year-over-year increase of 46.5%, with revenues projected at $1.16 billion, up 4.6% from the previous year [9][10]

Financial Data and Key Metrics Changes - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year [20] - ADHD portfolio net revenue was $13.2 million, compared to $13.8 million in the prior year, remaining flat with the previous quarter [20] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in the previous quarter, but down from $2.7 million in the prior year [18][21] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [22] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year [23] Business Line Data and Key Metrics Changes - The ADHD portfolio is experiencing a slight decrease in revenue due to a shift in marketing focus towards EXXUA and the introduction of generic competition [16][20] - The launch of an authorized generic for Adzenys has limited the impact of Teva's generic competition, with the authorized generic representing just under 20% of total prescriptions [17] - The pediatric portfolio saw a revenue increase due to reduced returns and stabilization of prescriptions, although it remains a non-core focus for the company [18] Market Data and Key Metrics Changes - The early feedback from patients on EXXUA has been positive, with reports of good tolerability and satisfaction [15] - Prescriptions for EXXUA have been written in 27 states, indicating broad market opportunity [14] - The majority of prescriptions are being filled through the RxConnect platform, with a favorable mix towards commercial insurance [48] Company Strategy and Development Direction - The company has launched EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive commercial launch strategy focused on prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers [11] - The company plans to maintain a focus on operational efficiency while scaling its promotional investments in line with performance [14][29] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the significant unmet need in the treatment of major depressive disorder, with 50%-60% of patients failing to achieve remission on current therapies [8][9] - The company expects to see a small initial ramp in EXXUA net revenue as it removes early access barriers and guarantees coverage for patients [26][27] - Management is optimistic about the early momentum of EXXUA and the potential for long-term growth, emphasizing the importance of cash flow for future expansion [39][40] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 during the quarter [23] - Adjusted EBITDA was -$0.8 million for the quarter, reflecting increased launch investments and a shift in marketing focus [25] - Cash and cash equivalents were $30 million at the end of the quarter, down from $32.6 million at the end of the previous quarter [25] Q&A Session Summary Question: Feedback from doctors on EXXUA prescriptions - Management noted mixed motivations for physicians to prescribe EXXUA, including interest in its mechanism of action and ease of prescribing through RxConnect [33][34][36] Question: Plans for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026 without sufficient cash flow and profitability to support it [38][39] Question: Direct-to-consumer campaign details - The campaign will focus on web-based strategies, including search engine optimization and social media, while maintaining compliance with FDA regulations [40][41] Question: Impact of weather on prescriptions - Management confirmed that recent weather events had a significant impact on prescriptions being filled and shipments to pharmacies, but supply issues have been resolved [46][53] Question: Supply ramp-up capabilities - Management assured that adequate supply is available to meet demand, with no issues anticipated in scaling production [53][54]

Financial Data and Key Metrics Changes - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year [20] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [21][22] - The company reported a net loss of $10.6 million, compared to a net income of $0.8 million in the prior year [23] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue was $13.2 million, a slight decrease from $13.8 million in the prior year and flat compared to the previous quarter [20][16] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in the previous quarter, but down from $2.7 million year-over-year [18][21] Market Data and Key Metrics Changes - Exxua prescriptions have been written in 27 states, with over 100 doctors prescribing it within the first month of launch [14][15] - The majority of prescriptions are being filled through the RxConnect platform, with a favorable mix towards commercial insurance [47] Company Strategy and Development Direction - The company has launched Exxua, the first FDA-approved 5-HT1A agonist for major depressive disorder, focusing on prescriber adoption and brand growth [4][31] - A comprehensive commercial launch strategy includes a motivated sales organization and targeted promotional efforts [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Exxua's market potential and early positive feedback from patients and prescribers [31][15] - The company is focused on maintaining operational efficiency while ramping up Exxua's market presence [29] Other Important Information - The company has a cash balance of $30 million as of December 31, 2025, down from $32.6 million at the end of the previous quarter [25] - The launch investment budget for Exxua has been reduced from $10 million to under $8 million due to execution efficiencies [29] Q&A Session Summary Question: Feedback from doctors prescribing Exxua - Early feedback indicates that physicians are motivated by the unique mechanism of action and the ease of prescribing through RxConnect [33][34] Question: Plans for sales force expansion - Management indicated that expansion would depend on achieving internal forecasts and cash flow, with no immediate plans for expansion in fiscal 2026 [38][39] Question: Direct-to-consumer campaign details - The campaign will focus on web-based strategies, including search engine optimization and social media, while maintaining compliance with regulations [40][41] Question: Impact of weather on prescription fulfillment - Weather has caused delays in prescriptions being filled, but the company has adequate supply to meet demand [46][53]

Financial Data and Key Metrics Changes - Net revenue for Q2 2026 was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million last year [19][20] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [21][22] - The company reported a net loss of $10.6 million or $5 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [23][24] Business Line Data and Key Metrics Changes - ADHD net revenue was $13.2 million, flat compared to Q1 2026, despite a slight decrease from the previous year, attributed to a shift in marketing focus towards EXXUA [16][19] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in Q1 2026, but decreased from $2.7 million in the prior year [18][20] Market Data and Key Metrics Changes - The launch of EXXUA has seen prescriptions written from 27 states, with over 100 doctors prescribing it within the first month [13][14] - Most prescriptions are being filled through the RxConnect platform, with a significant portion also coming from retail pharmacies [46] Company Strategy and Development Direction - The company is focused on the commercial launch of EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive strategy aimed at prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers and leveraging the RxConnect platform for patient access [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from patients on EXXUA, noting good tolerability and satisfaction [15] - The company anticipates a gradual ramp-up in EXXUA net revenue as initial barriers to access are removed, with expectations for increased prescriptions ahead of revenue recognition [27][30] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 for Cotempla during the quarter [22] - Adjusted EBITDA was -$0.8 million for Q2 2026, down from $1.3 million in the prior year [25] Q&A Session Summary Question: Feedback from doctors prescribing EXXUA - Management noted mixed motivations for early prescriptions, including interest in the mechanism of action and ease of prescribing through RxConnect [33][34] Question: Expectations for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026, with triggers for expansion tied to achieving internal forecasts and cash flow [37][38] Question: Direct-to-consumer campaign details - The campaign will be web-based, focusing on search engine optimization and social media, while maintaining compliance with FDA regulations [39][40] Question: Impact of weather on prescription filling - Management confirmed significant weather impacts on script filling and shipments, but noted that supply issues have been corrected [44][51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-0883144 | | -- ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host confer ...

Core Insights - The company reported total net revenue of $15.2 million for the fiscal 2026 second quarter [1] - Adjusted EBITDA was $(0.8) million, which includes investments of $30.0 million for the launch of EXXUA [1] - The company launched EXXUA™ (gepirone) extended-release tablets in December 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] Financial Performance - Total net revenue for the quarter was $15.2 million [1] - Adjusted EBITDA was negative at $(0.8) million, reflecting the costs associated with the EXXUA launch [1] - The company had a cash balance of $30.0 million as of December 31, 2025 [1] Product Launch - EXXUA™ (gepirone) was launched in December 2025 as a key component of the company's commercial strategy [1] - The product aims to penetrate the significant U.S. market for major depressive disorder, valued at over $22 billion [1] Upcoming Events - The company will host a conference call and webcast on February 3, 2026, at 4:30 p.m. Eastern time to discuss the results [1]

Medicines Made for Life Nasdaq: AYTU February 2026 Actor portrayals. Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the futu ...